4th Quarter - Report

CROSSROADS STRATEGIES, LLC for INDIVIOR INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues related to overdose reversal products; H.R.4531/S.3393, SUPPORT for Patients and Communities Reauthorization Act; H.R.4007/S.2809, Halting the Epidemic of Addiction and Loss Act of 2023; H.R.9029/S.4942, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; H.R.8070/S.4638, National Defense Authorization Act for Fiscal Year 2025, issues related to Naloxone; H.R.10445, Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4007 (118th), H.R. 10445 (118th), H.R. 8070 (118th), S. 4942 (118th), H.R. 4531 (118th), S. 3393 (118th), H.R. 9029 (118th), S. 2809 (118th), S. 4638 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.